Day: October 25, 2021

BEDMINSTER, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform delivery technology, today announced that Matinas BioPharma has been selected for inclusion in the B. Riley Fall 2021 Growth Biotech Best Ideas Series. As part of the series, Jerome D. Jabbour, Chief Executive Officer of Matinas, and other members of the Matinas leadership team will participate in a fireside chat on Tuesday, November 23, 2021. Fireside chat details:Topic Applying Targeted Intracellular Drug Delivery with an Innovative Lipid Nano-Crystal Platform for Life Threatening Acute & Chronic Disease Settings   Date Tuesday, November...

SAN FRANCISCO, Oct. 25, 2021 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN), today announced that analyses from the global Phase 3 roxadustat clinical program will be presented at the American Society of Nephrology Kidney Week 2021 taking place virtually November 4 – 7, 2021. A total of 18 presentations will be presented by FibroGen, or its collaboration partners AstraZeneca and Astellas Pharma, Inc., at this year’s meeting. Eleven of the presentations are related to phase 3 studies of roxadustat for the treatment of anemia associated with CKD. An additional seven presentations are related to CKD anemia epidemiology and disease state which outline the burden of anemia on CKD patients and the continued unmet medical need for innovative therapies. The accepted abstracts are now available on the ASN website at https://bit.ly/3FTP53Z Roxadustat/CKD...

LONDON, Oct. 25, 2021 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2021 financial results and operational highlights before open of U.S. markets on Wednesday, November 3, 2021. Management will host a conference call and webcast at 8:30 am ET/1:30 pm GMT to discuss the company’s financial results and provide a general business update. To listen to the webcast and view the accompanying slide presentation, please go to the events section of Autolus’ website. The call may also be accessed by dialing (866) 679-5407 for U.S. and Canada callers or (409) 217-8320 for international callers. Please reference conference ID 6984737. After the conference call, a replay will...

Thirty-Three In-Venue Activations of Versus Products during the week of October 18th, When Nearly 1 Million Fans Viewed Versus Products LOS ANGELES, Oct. 25, 2021 (GLOBE NEWSWIRE) — Versus Systems Inc. (“Versus” or the “Company”) (Nasdaq: VS) today announced that the company conducted thirty-three activations of its fan engagement products during the week of October 18, 2021, the highest number to date in the company’s history. The in-venue activations were done at stadiums across the world, in multiple sports leagues, as fans increasingly return to watching sports in-person. Throughout the week, fans of teams in the NFL, NBA, NHL, MLS, NCAA, AHL, and Nippon Professional Baseball League played live, interactive games such as Trivia, Match Game, Plinko, Tug of War, and many others in-venue during the games and matches where Versus...

ConnectMiles Accelerator enables members to reach their rewards fasterCopa Airlines introduces option for ConnectMiles members to multiply their miles, powered by Points InternationalConnectMiles Accelerator enables members to reach their rewards fasterTORONTO, Oct. 25, 2021 (GLOBE NEWSWIRE) — Good news for Copa Airlines’ ConnectMiles members looking to maximize their miles as demand for travel increases. Just launched by Copa Airlines, one of the foremost airlines in Latin America, ConnectMiles Accelerator provides customers with the option to pay a preferential rate to boost their miles balance and reach their rewards goal sooner. Enabled by global leader in loyalty commerce, Points (Nasdaq: PCOM) (TSX: PTS), Accelerator will let ConnectMiles members multiply miles earned via flying, credit card spend, online...

ATLANTA, Oct. 25, 2021 (GLOBE NEWSWIRE) — First Advantage Corporation (NASDAQ: FA), a leading global provider of technology solutions for screening, verifications, safety and compliance related to human capital, will issue its third quarter 2021 financial results on Monday, November 8, 2021 prior to the Company’s earnings conference call, which will be held at 8:30 a.m. ET on the same day. Conference Call Details To participate in the conference call, please dial (877) 313-2269 (domestic) or (470) 495-9550 (international) approximately ten minutes before the 8:30 a.m. ET start. Please mention to the operator that you are dialing in for the First Advantage third quarter 2021 earnings call or provide the conference code 8697546. The call will also be webcast live on the Company’s investor relations website at https://investors.fadv.com...

Father of Fiber Laser Industry Commercialized Innovative Laser Technology Changing Industrial Manufacturing OXFORD, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) — It is with profound sadness that IPG Photonics announces the passing of beloved founder and Chairman and former CEO Dr. Valentin P. Gapontsev. Dr. Eugene Scherbakov, Chief Executive Officer, said “Valentin’s passing is a tremendous loss for the IPG community and the larger photonics world. Valentin’s technical innovations, strategic vision for the capabilities of fiber lasers and entrepreneurial drive transformed the laser industry and industrial automation to the point where lasers are finally cost-effective, reliable and effective tools that have mass applications in global industrial production. Recognized as the Father of the Fiber Laser Industry, his leadership and unique...

  Paris, October 25, 2021,   Disclosure of Transactions in Own Shares   In accordance with the authorization given by the shareholders’ annual meeting on July 6, 2021 to trade on its own shares and pursuant to applicable law on share repurchase, Kering (LEI: 549300VGEJKB7SVUZR78) declares the following purchases of its own shares (FR0000121485) from October 18 to 22, 2021:  Issuer’s name Issuer’s identifying code Date of transaction Identifying code of financial instrument Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares Market (MIC code)KERING 549300VGEJKB7SVUZR78 18/10/2021 FR0000121485 6 348 648,5071 XPARKERING 549300VGEJKB7SVUZR78 19/10/2021 FR0000121485 4 359 650,0809 XPARKERING 549300VGEJKB7SVUZR78 19/10/2021 FR0000121485...

CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) — TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced a clinical trial collaboration agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate gavo-cel in combination with Opdivo® (nivolumab) and Yervoy® (ipilimumab) in its planned Phase 2 clinical trial in treatment refractory mesothelin-expressing solid tumors. The primary objective of the Phase 2 trial is to evaluate the efficacy of gavo-cel in patients with unresectable, metastatic or recurrent mesothelin-expressing cancers including non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma (MPM) and cholangiocarcinoma. TCR2 is sponsoring the Phase 2 trial. “We are...